Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$8.44 USD
-0.40 (-4.52%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Maravai LifeSciences Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 575 | 632 | 551 | 236 | 25 |
Receivables | 56 | 147 | 118 | 51 | 18 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 51 | 43 | 52 | 33 | 14 |
Other Current Assets | 18 | 26 | 20 | 11 | 4 |
Total Current Assets | 700 | 848 | 740 | 332 | 61 |
Net Property & Equipment | 163 | 53 | 46 | 101 | 94 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 766 | 808 | 432 | 0 |
Intangibles | 547 | 500 | 270 | 402 | 422 |
Deposits & Other Assets | 78 | 116 | 53 | 4 | 1 |
Total Assets | 1,487 | 2,282 | 1,918 | 1,271 | 578 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 6 | 8 | 8 | 7 |
Current Portion Long-Term Debt | 5 | 5 | 6 | 6 | 3 |
Current Portion Capital Leases | 1 | 0 | 0 | 0 | 0 |
Accrued Expenses | 60 | 53 | 35 | 39 | 19 |
Income Taxes Payable | 7 | 42 | 35 | 0 | 0 |
Other Current Liabilities | 3 | 3 | 10 | 78 | 1 |
Total Current Liabilities | 87 | 110 | 94 | 131 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 9 | 15 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 519 | 522 | 525 | 529 | 335 |
Non-Current Capital Leases | 32 | 0 | 0 | 56 | 53 |
Other Non-Current Liabilities | 59 | 745 | 755 | 392 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 698 | 1,377 | 1,373 | 1,116 | 433 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 184 |
Capital Surplus | 129 | 138 | 128 | 85 | 0 |
Retained Earnings | 286 | 405 | 185 | 1 | -42 |
Other Equity | 373 | 360 | 230 | 66 | 3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 790 | 905 | 545 | 155 | 145 |
Total Liabilities & Shareholder's Equity | 1,487 | 2,282 | 1,918 | 1,271 | 578 |
Total Common Equity | 790 | 905 | 545 | 155 | 145 |
Shares Outstanding | 251.30 | 255.20 | 255.10 | 257.60 | NA |
Book Value Per Share | 3.14 | 3.55 | 2.14 | 0.60 | 0.00 |
Fiscal Year End for Maravai LifeSciences Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 573 | 562 | 575 | 580 | 580 |
Receivables | 39 | 40 | 56 | 49 | 49 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 49 | 50 | 51 | 49 | 47 |
Other Current Assets | 24 | 17 | 18 | 23 | 23 |
Total Current Assets | 685 | 668 | 700 | 701 | 699 |
Net Property & Equipment | 166 | 162 | 163 | 154 | 142 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 774 | 770 |
Intangibles | 533 | 540 | 547 | 554 | 561 |
Deposits & Other Assets | 63 | 75 | 78 | 86 | 93 |
Total Assets | 1,448 | 1,445 | 1,487 | 2,268 | 2,264 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 8 | 11 | 9 | 7 |
Current Portion Long-Term Debt | 5 | 5 | 5 | 5 | 5 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 41 | 35 | 60 | 56 | 50 |
Income Taxes Payable | 7 | 7 | 7 | 4 | 9 |
Other Current Liabilities | 2 | 2 | 3 | 3 | 2 |
Total Current Liabilities | 69 | 59 | 87 | 78 | 75 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 7 | 9 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 517 | 518 | 519 | 520 | 520 |
Non-Current Capital Leases | 32 | 32 | 32 | 32 | 32 |
Other Non-Current Liabilities | 54 | 59 | 739 | 731 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 671 | 667 | 698 | 1,375 | 1,367 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 168 | 134 | 129 | 125 | 120 |
Retained Earnings | 266 | 274 | 286 | 392 | 398 |
Other Equity | 339 | 367 | 373 | 373 | 377 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 776 | 777 | 790 | 892 | 898 |
Total Liabilities & Shareholder's Equity | 1,448 | 1,445 | 1,487 | 2,268 | 2,264 |
Total Common Equity | 776 | 777 | 790 | 892 | 898 |
Shares Outstanding | 252.10 | 251.70 | 251.30 | 251.00 | 251.00 |
Book Value Per Share | 3.08 | 3.09 | 3.14 | 3.55 | 3.58 |